Ziprasidone

Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) [1].

Product Specifications

CAS Number

[146939-27-7]

Product Name Alternative

CP-88059

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ziprasidone.html

Purity

99.35

Solubility

DMSO : 13.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5

Molecular Formula

C21H21ClN4OS

Molecular Weight

412.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Rollema H, et al. 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48 (3) :229-237.|[2]Zhi Su, et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol. 2006 Jan 12;71 (3) :278-86.|[3]Subin Park, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012 Jun;61 (6) :787-93.